Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment




Cardiology Homepage

Medical community finds ways to make TAVR safer for at-risk patients Improving outcomes with special procedures

New ultrasound tech could help detect pediatric congenital heart disease Visualizes structure and blood flow of babies' hearts

Mick Jagger resting after TAVR heart surgery The 75 year old rock star is reportedly recovering from the operation at New York Presbyterian

DHS warns some Medtronic implantable defibrillators vulnerable to hacking Software patch should resolve issue, recall not expected

New AI software identifies make and model of cardiac implants in seconds Speed up diagnosis and delivery of treatment for patients with faulty devices

Getting to the heart of cardiac ultrasound technology From premium systems to point of care, an expanding market

FDA gives thumbs-up to Genetesis MCG cardiac imaging system Measures magnetic fields produced by heart's electrical activity

Apple study suggests wearable technology may be useful in detecting atrial fibrillation May assist in stroke and hospitalization prevention

Echocardiogram should play role in patient selection for transcatheter mitral valve repair, says study New study highlighted at ACC

FDA gives green light for smallest, slimmest 3T CRM devices Extended battery lives, greater diagnostic and therapeutic capabilities

SAPIEN 3 Ultra System

FDA gives green light for Edwards' SAPIEN 3 Ultra system

by John R. Fischer , Staff Reporter
Edwards Lifesciences Corporation has been given a green light from the FDA to initiate sales of its SAPIEN 3 Ultra system.

Designed for transcatheter aortic valve replacement, the solution stands as an alternative to patients with severe symptomatic aortic stenosis who face intermediate or greater risks from open-heart surgery.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED

"The advanced SAPIEN 3 Ultra system features enhancements on the valve and a new delivery system to address the needs of both patients and clinicians, building on our best-in-class performance of SAPIEN 3 to further advance and improve patient care," Larry L. Wood, Edwards' corporate vice president of transcatheter heart valves, said in a statement. "We look forward to introducing the SAPIEN 3 Ultra system to U.S. patients."

Created with an “on balloon” design, the valve requires no aligning during procedures and does not incur the risk of paracalvular leaks due to its heightened outer skirt. It also comprises a low-profile 14-French Axela expandable sheath and comes in three sizes: 20, 23 and 26 mm.

The system was cleared and introduced this November in Europe, as part of a controlled rollout that includes training to ensure high procedural success of the advanced valve and delivery system. It was not, however, released in Germany, due to a preliminary injunction brought forth by Boston Scientific on its future sales and use back in October, with the courts there upholding the ruling.

A U.S. jury recently awarded $35 million in damages to Boston Scientific for infringement by Edwards of a patent for a transcatheter heart valve sealing skirt. Edwards does not expect to pay the award due to a determination earlier this year by the U.S. Patent and Trademark office that all asserted claims of the specific patent were invalid. It also plans to appeal a decision by the jury that found Edwards' foundational U.S. Spenser Patents for transcatheter heart valves to be valid but not infringed on by Boston Scientific’s Lotus valve.

Having previously gained clearance for aortic and mitral valve-in-valve procedures, the solution has shown its worth not just in terms of care but as a cost-saving alternative to surgery. A recent trial found that use of the SAPIEN 3 valve saved patients nearly $16,000 in total one-year costs, on average, compared to surgical aortic valve replacement. Average index hospitalization costs, which include the price of the procedure, hospital stay and physician fees, were also lower.

"The Edwards SAPIEN 3 Ultra system provides meaningful technology improvements that help further optimize the transcatheter aortic valve replacement procedure, adding simplicity and advancing patient care," John Webb, director of interventional cardiology and cardiac catheterization laboratories at St. Paul's Hospital in Vancouver, and a professor of cardiology at the University of British Columbia, said in a statement.

Cardiology Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.